Frontiers in Aging Neuroscience (Apr 2022)
Platelet Activating Factor Receptor Exaggerates Microglia-Mediated Microenvironment by IL10-STAT3 Signaling: A Novel Potential Biomarker and Target for Diagnosis and Treatment of Alzheimer’s Disease
- Junxiu Liu,
- Junxiu Liu,
- Junxiu Liu,
- Junxiu Liu,
- Linchi Jiao,
- Linchi Jiao,
- Linchi Jiao,
- Linchi Jiao,
- Xin Zhong,
- Xin Zhong,
- Xin Zhong,
- Xin Zhong,
- Weifan Yao,
- Weifan Yao,
- Weifan Yao,
- Weifan Yao,
- Ke Du,
- Ke Du,
- Ke Du,
- Ke Du,
- Senxu Lu,
- Senxu Lu,
- Senxu Lu,
- Senxu Lu,
- Yuqiang Wu,
- Yuqiang Wu,
- Yuqiang Wu,
- Yuqiang Wu,
- Tianxin Ma,
- Tianxin Ma,
- Tianxin Ma,
- Tianxin Ma,
- Junhui Tong,
- Junhui Tong,
- Junhui Tong,
- Junhui Tong,
- Mingyue Xu,
- Mingyue Xu,
- Mingyue Xu,
- Mingyue Xu,
- Wenjuan Jiang,
- Wenjuan Jiang,
- Wenjuan Jiang,
- Wenjuan Jiang,
- Yubao Wang,
- Miao He,
- Miao He,
- Miao He,
- Miao He,
- Wei Xin,
- Wei Xin,
- Mingyan Liu,
- Mingyan Liu,
- Mingyan Liu,
- Mingyan Liu
Affiliations
- Junxiu Liu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Junxiu Liu
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Junxiu Liu
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Junxiu Liu
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Linchi Jiao
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Linchi Jiao
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Linchi Jiao
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Linchi Jiao
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Xin Zhong
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Xin Zhong
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Xin Zhong
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Xin Zhong
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Weifan Yao
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Weifan Yao
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Weifan Yao
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Weifan Yao
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Ke Du
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Ke Du
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Ke Du
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Ke Du
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Senxu Lu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Senxu Lu
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Senxu Lu
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Senxu Lu
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Yuqiang Wu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Yuqiang Wu
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Yuqiang Wu
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Yuqiang Wu
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Tianxin Ma
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Tianxin Ma
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Tianxin Ma
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Tianxin Ma
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Junhui Tong
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Junhui Tong
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Junhui Tong
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Junhui Tong
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Mingyue Xu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Mingyue Xu
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Mingyue Xu
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Mingyue Xu
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Wenjuan Jiang
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Wenjuan Jiang
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Wenjuan Jiang
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Wenjuan Jiang
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Yubao Wang
- Liaoning Medical Diagnosis and Treatment Center, Shenyang, China
- Miao He
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Miao He
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Miao He
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Miao He
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- Wei Xin
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Wei Xin
- The First Affiliated Hospital of China Medical University, Shenyang, China
- Mingyan Liu
- Department of Pharmacology, School of Pharmacy, China Medical University, Shenyang, China
- Mingyan Liu
- Liaoning Key Laboratory of Molecular Targeted Anti-Tumor Drug Development and Evaluation, China Medical University, Shenyang, China
- Mingyan Liu
- Liaoning Cancer Immune Peptide Drug Engineering Technology Research Center, China Medical University, Shenyang, China
- Mingyan Liu
- Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, China Medical University, Shenyang, China
- DOI
- https://doi.org/10.3389/fnagi.2022.856628
- Journal volume & issue
-
Vol. 14
Abstract
BackgroundEarly diagnosis and effective intervention are the keys to delaying the progression of Alzheimer’s Disease (AD). Therefore, we aimed to identify new biomarkers for the early diagnosis of AD through bioinformatic analysis and elucidate the possible underlying mechanisms.Methods and ResultsGSE1297, GSE63063, and GSE110226 datasets from the GEO database were used to screen the highly differentially expressed genes. We identified a potential biomarker, Platelet activating factor receptor (PTAFR), significantly upregulated in the brain tissue, peripheral blood, and cerebrospinal fluid of AD patients. Furthermore, PTAFR levels in the plasma and brain tissues of APP/PS1 mice were significantly elevated. Simultaneously, PTAFR could mediate the inflammatory responses to exaggerate the microenvironment, particularly mediated by the microglia through the IL10-STAT3 pathway. In addition, PTAFR was a putative target of anti-AD compounds, including EGCG, donepezil, curcumin, memantine, and Huperzine A.ConclusionPTAFR was a potential biomarker for early AD diagnosis and treatment which correlated with the microglia-mediated microenvironment. It is an important putative target for the development of a novel strategy for clinical treatment and drug discovery for AD.
Keywords
